Close Menu

NEW YORK – Invitae reported after the close of the market Wednesday that its fourth quarter 2019 revenues increased 47 percent from the prior year.

For the three months ended Dec. 31, 2019, Invitae reported $66.3 million in revenues compared to $45.4 million in Q4 2018, falling short of the consensus Wall Street estimate of $68.1 million. Invitae reported testing revenue of $65.1 million for the quarter, as well as $1.2 million in other revenue.

Invitae accessioned around 148,000 samples in Q4 2019 compared to more than 87,000 samples in Q4 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.